Pharmacotherapy Prescribing to Patients with Concurrent Tobacco and Alcohol Use Disorder in a Large, Urban, Integrated Health System
Tobacco use disorder (TUD) and alcohol use disorder (AUD) are two leading causes of preventable death in the USA. These disorders frequently occur concurrently, leading to multiplicative effects on morbidity and mortality.1 Treatment of AUD and TUD with pharmacotherapy is an evidence-based way to reduce these harms. The prevalence of pharmacotherapy prescribing for patients with coexisting AUD and TUD is poorly understood. We conducted a retrospective cohort study to determine the prevalence of prescribing of AUD and TUD pharmacotherapy in a population with both diagnoses.
We conducted a retrospective cohort study using electronic health record data from Montefiore Health System between January 2010 and December 2014. Montefiore Health System is a large urban academic medical center and integrated health care system in the Bronx, New York, with over 3 million outpatient visits annually at a network of almost 100 primary and specialty care clinics.
This study was funded in part by grant from the National Institute on Drug Abuse of the National Institutes of Health (K24DA036955 and K08DA043050). The funding agency had no role in design of the study, collection, analysis, and interpretation of data, or in writing the manuscript.
Compliance with Ethical Standards
The study was approved by the Albert Einstein College of Medicine Institutional Review Board.
Conflict of Interest
The authors declare that they do not have a conflict of interest.